Molecular Health appoints Christian Meisel, MD, PhD, as Chief Medical Officer

Molecular Health appoints Dr. Christian Meisel as corporate Chief Medical Officer (CMO).
Dr. Meisel comes to Molecular Health with over 25 years of experience in the healthcare sector – including clinical practice and research & development across academia and the biopharmaceutical industry – and more than 10 years in senior pharma leadership roles. As an MD and PhD with additional qualifications in computer science and extensive experience in precision medicine, Dr. Meisel will be responsible for all clinical aspects of Molecular Health’s portfolio and development. As a member of the company’s leadership, he will also provide strategic direction and leadership in the development of Molecular Health.

Learn more
See more news

Read more

Molecular Health Licenses its Proprietary Predictive Analytics to DATEN CAPITAL

Molecular Health has granted an exclusive license for Molecular Health Predict (MH Predict) to DATEN CAPITAL LLP (DATEN), for its use in the financial industry. MH Predict was developed by Molecular Health to calculate the likelihood of success of drug clinical trials, and DATEN is a private limited liability partnership founded to commercialize data-science, AI-driven approaches to investing. Molecular Health will receive an annual license fee as well as success-based payments from DATEN.

Learn more
See more news

Read more

MH Guide for labs: Augment your annotations quickly

Benefit from our software-aided interpretations for personalized cancer treatment
• Latest and comprehensive clinical evidence gathered from top publications/databases
• Oncologist/pathologist reviewed annotations that include treatment options
• Seamless integration into existing lab workflow
• Intuitive UI/UX
• Cloud-based portal for rapid and secure processing

Learn more
See more news

Read more

Molecular Health appoints Christian Meisel, MD, PhD, as Chief Medical Officer

Molecular Health appoints Dr. Christian Meisel as corporate Chief Medical Officer (CMO).
Dr. Meisel comes to Molecular Health with over 25 years of experience in the healthcare sector – including clinical practice and research & development across academia and the biopharmaceutical industry – and more than 10 years in senior pharma leadership roles. As an MD and PhD with additional qualifications in computer science and extensive experience in precision medicine, Dr. Meisel will be responsible for all clinical aspects of Molecular Health’s portfolio and development. As a member of the company’s leadership, he will also provide strategic direction and leadership in the development of Molecular Health.

Learn more
See more news

Molecular Health Licenses its Proprietary Predictive Analytics to DATEN CAPITAL

Molecular Health has granted an exclusive license for Molecular Health Predict (MH Predict) to DATEN CAPITAL LLP (DATEN), for its use in the financial industry. MH Predict was developed by Molecular Health to calculate the likelihood of success of drug clinical trials, and DATEN is a private limited liability partnership founded to commercialize data-science, AI-driven approaches to investing. Molecular Health will receive an annual license fee as well as success-based payments from DATEN.

Learn more
See more news

MH Guide for labs: Augment your annotations quickly

Benefit from our software-aided interpretations for personalized cancer treatment
• Latest and comprehensive clinical evidence gathered from top publications/databases
• Oncologist/pathologist reviewed annotations that include treatment options
• Seamless integration into existing lab workflow
• Intuitive UI/UX
• Cloud-based portal for rapid and secure processing

Learn more
See more news

Molecular Health launches MH Mendel for the genetic diagnosis of hereditary diseases

MH Mendel has been launched for the genetic diagnosis of hereditary diseases.

As an integral part of the IVD product MH Guide 3.0, it supports human geneticists in creating a diagnostic report based on their own variant classifications. MH Mendel combines the information that is most relevant for the diagnosis of hereditary diseases. It includes population frequencies, reported clinical significance, and functional impact predictions for a plethora of variants.

Read more
See more news

Molecular Health launches MH Guide version 3.0

Molecular Health has launched Version 3.0 of MH Guide, a comprehensive software solution for precision medicine. MH Guide compares patient-specific molecular information with biomedical knowledge to deliver an interactive, editable, medical report that supports treating physicians in evaluating the range of therapy options identified for the unique genomic profile of the patient.

The new version adds new features for intuitive biomarker classification and improved usability. MH Guide is registered as an in vitro diagnostic device in the EU.

Read more
See more news

Molecular Health receives grant from Bill & Melinda Gates Foundation

Molecular Health was awarded a grant from the Bill & Melinda Gates Foundation.

Through the program enabled by the grant, Molecular Health will leverage computational biomedicine technology and domain expertise captured in MH core assets, Dataome® knowledgebase and MH Effect® software, to help find shorter, more effective and better-tolerated treatment regimens for TB, and to explore ways to address perinatal complications in developing countries.

Read more
See more news

Unlock knowledge at the molecular level

MH Guide makes interpreting and reporting of clinical variants faster, easier and more accurate. In fact, clinical annotation and molecular data processing that used to take days now takes minutes.

MH Guide 2.3 contains:
• Interpretation of combination biomarkers
• The option of reporting wildtype Clinical Variant Interpretations (CVIs)
• Summary statistics on mutational load
• Encryption of PHI data

Read more
See more news

Magazin Life Sciences „Präzisionsmedizin durch Big Data“

Mit einer Fallstudie zum Thema „Präzisionsmedizin durch Big Data“ ist Molecular Health in der aktuellen Ausgabe des Investormagazins „Personalisierte Medizin“ der GoingPublic Media AG vertreten. Direkt zum E-Magazin führt...

123. DGIM Kongress – Panel Präzisionsmedizin

Besuchen Sie unser Panel „Präzisionsmedizin: Grundlagen, klinische Wirklichkeit und Ausblick“ auf dem DGIM Kongress im Congress Center Rosengarten Mannheim. Es findet am Sonntag 30.04.2017, ab 08:00 Uhr im Saal 21 statt und beleuchtet das Thema der digitalen Medizin....

apotheke adhoc über „Algorithmen für Arzneimittel“

apotheke adhoc schreibt über Molecular Health und neue Diagnoseverfahren: Die Krebstherapie steht nach Einschätzung von Wissenschaftlern, Ärzten und Herstellern in den kommenden Jahren vor einer Revolution. Neue Diagnoseverfahren und darauf...

Molecular Health stärkt Managementteam in den USA

Gerry Sheridan zum Chief Financial Officer und Dr. Les Paul zum Chief Medical Officer ernannt Heidelberg, Deutschland und Boston, USA – 21. Juli 2016 – Molecular Health, ein Unternehmen der Präzisionsmedizin, das sich auf die Vermarktung von...

Sequencing and medical services in the US

Molecular Health will no longer provide its end-to-end cancer diagnostic medical services in the US and thus will terminate processing patient cases effective August 19, 2016. In order to honor our turn-around time commitments, we will not be accepting any new patient...

ApoForum der Deutschen Apotheker- und Ärztebank am 29.06.2016

Molecular Health war mit einem Fachexperten als Referent zu Gast bei der Podiumsdiskussion des diesjährigen ApoForums „Digital Health – Disruption oder Evolution der Gesundheitsversorgung?“ am 29. Juni in Düsseldorf. Dr. Mathias Göschl (Vice President, Content)...

IIR Austria Spital 2016 – Wien

Mit einem Vortrag zur „Evidenzbasierten molekularen Dateninterpretation in der personalisierten Tumortherapie“ von Dr. Sandra Morandell präsentierte sich Molecular Health auf der diesjährigen IIR Spital 2016 in Vösendorf bei Wien und stieß auf großes Interesse bei den...

Digitalisierung der Medizin in Bayern – Fokus klinische Patientendaten

Auf Einladung des Bayerischen Staatsministeriums für Wirtschaft und Medien, Energie und Technologie hat Friedrich von Bohlen, CEO von Molecular Health, am 30.06.2016 einen Impulsvortrag zum Thema „Precision Medicine“ im Rahmen der Veranstaltung „Digitalisierung der...